Oncimmune Holdings plc (ONC.L)
- Previous Close
24.50 - Open
22.20 - Bid 22.20 x --
- Ask 25.00 x --
- Day's Range
22.20 - 24.38 - 52 Week Range
13.00 - 45.00 - Volume
4,000 - Avg. Volume
75,510 - Market Cap (intraday)
17.637M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.08 - Earnings Date May 29, 2024 - Jun 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.
www.oncimmune.comRecent News: ONC.L
Performance Overview: ONC.L
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONC.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONC.L
Valuation Measures
Market Cap
18.16M
Enterprise Value
20.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.43
Price/Book (mrq)
27.65
Enterprise Value/Revenue
17.58
Enterprise Value/EBITDA
-4.57
Financial Highlights
Profitability and Income Statement
Profit Margin
356.25%
Return on Assets (ttm)
-26.38%
Return on Equity (ttm)
--
Revenue (ttm)
1.15M
Net Income Avi to Common (ttm)
-6.15M
Diluted EPS (ttm)
-0.08
Balance Sheet and Cash Flow
Total Cash (mrq)
3.21M
Total Debt/Equity (mrq)
806.85%
Levered Free Cash Flow (ttm)
-4.41M
Company Insights: ONC.L
ONC.L does not have Company Insights